Form 4: PharmaCyte Director Reports Stock & Option Changes

PharmaCyte Biotech Director Robert Weinstein reported the acquisition of common stock and stock options, alongside a tax-related disposal of shares.

Summary

• Robert Weinstein, a Director at PharmaCyte Biotech, Inc. (PMCB), reported changes in his beneficial ownership.
• On December 12, 2025, Mr. Weinstein acquired 75,000 shares of Common Stock at a price of $0.
• Concurrently, on December 12, 2025, 33,750 shares of Common Stock were disposed of at a price of $1.02. This disposal represents shares withheld by the Issuer to satisfy tax liability upon the vesting of restricted stock units and was not an open-market transaction.
• Following these transactions, Mr. Weinstein beneficially owns 41,250 shares of Common Stock directly.
• On April 25, 2025, Mr. Weinstein acquired 63,233 stock options with an exercise price of $1.22.
• These stock options are set to vest in full on the date of the Issuer's next annual meeting of stockholders, contingent on Mr. Weinstein's continued service.
• The stock options have an expiration date of April 24, 2035.
• The filing of this transaction report was late due to an inadvertent administrative error, not an error by Mr. Weinstein.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive due to the director's acquisition of additional equity and options, indicating continued alignment with the company. The late filing is a minor administrative issue, and the share disposal is a standard tax event.

Positives

• Director Robert Weinstein acquired 75,000 shares of common stock, increasing his direct ownership stake.
• Mr. Weinstein was granted 63,233 stock options, aligning his interests with shareholder value through future potential gains.

Negatives

• The Form 4 filing was late due to an administrative error, which can be a minor governance concern.
• 33,750 shares were disposed of to cover tax liabilities, reducing the director's direct share count, though this is a common practice for vested equity awards.

Risks

• The vesting of the 63,233 stock options is subject to Mr. Weinstein's continued service to the company, meaning the options could be forfeited if his service ceases before the next annual meeting.

Future Outlook

The 63,233 stock options granted to Director Robert Weinstein are expected to vest in full on the date of PharmaCyte Biotech's next annual meeting of stockholders, provided he continues his service to the company.

Management Comments

• The transaction report was late due to an inadvertent administrative error and not any error of Mr. Weinstein.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, common across all publicly traded companies. It reflects a director's compensation structure, including equity awards and tax-related share withholdings, rather than a strategic business update or operational performance indicator for the biotechnology industry.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: The director's increased equity stake and option grants align his interests with long-term shareholder value.
• Employees: The vesting condition tied to continued service is a common incentive mechanism for key personnel.

Next Steps

• The 63,233 stock options will vest on the date of the Issuer's next annual meeting of stockholders, subject to Robert Weinstein's continued service.

Key Dates

Keywords

PharmaCyte Biotech, PMCB, Robert Weinstein, Form 4, Insider Trading, Beneficial Ownership, Stock Options, Common Stock, Director, Equity Compensation